Enhertu Business Briefing

from the beginning

ENHERTU Business Briefing

Forward-Looking Statements

Presenters

Opening

ENHERTU Business Briefing

Transforming into a Global Oncology Leader

Strong Global Performance

All Four Regions Delivering:Global Net Sales have Exceeded 100 Bn JPY Per Quarter

Growth Opportunities Remain in Current Indications,Including HER2+ mBC 2L

Growth Opportunities Remain in Current Indications,Including HER2 low mBC (post chemo)

ENHERTU Has Multiple Potential Growth Catalysts

If Approved, New Indications for ENHERTU Will More Than Double the Patients Eligible for ENHERTU in 2026

The Eligible Patient Opportunity for ENHERTU Will Grow to > 100k in 2026

EXPANDING ONCOLOGY PORTFOLIO Yields Thirteen New Portfolio Growth Catalysts in the Next Three Years

HER3DXd: HERTHENA Lung01 Opportunity

DatoDXd : TROPION Lung01 Opportunity

Dato-DXd: TROPION-Breast01 Opportunity

Our Expanding Portfolio Will Dramatically Increase our Opportunity to Help Patients with Cancer

The Eligible Patient Opportunity for ENHERTU, Dato DXd and HER3 DXd Approaches Nearly 500k in the Major Markets

IDXd and DS 6000 (R DXd ) are Expected to be the Fourth and Fifth DXd ADCs to Launch in the Market

By 2030, Daiichi Sankyo Could Have Five Marketed ADCs in Over 30 Indications, Serving Nearly 400k Patients

DAIICHI SANKYO IS Progressing Toward its “Top Ten” Goal

DAIICHI SANKYO’S ONCOLOGY PORTFOLIO HAD THE Highest Growth in CY 2023

DAIICHI SANKYO REMAINS HIGHLY CONFIDENT THAT We Will Reach Our Goal and Exceed Our Commitment

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6